<DOC>
	<DOCNO>NCT00099541</DOCNO>
	<brief_summary>This trial evaluate two separate group patient stage IIIB/IV non-small cell lung cancer . The objective Group 1 investigate FDA-approved drug stage IIIB/IV non-small cell lung cancer patient spread bone . The objective Group 2 see blood test use predict cancer-related bone lesion develop . This trial seek patient 18 year old diagnose Stage IIIB Stage IV non-small cell lung cancer treat surgery .</brief_summary>
	<brief_title>Non-small Cell Lung Cancer Registry</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Pleural Effusion , Malignant</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Age great equal 18 year Histologically confirm NSCLC ( squamous cell carcinoma , adenocarcinoma , large cell carcinoma ) . Unresectable Stage IIIB pleural effusion stage IV NSCLC ECOG performance status 0 1 Patients receive IV bisphosphonate ( e.g.pamidronate ; zoledronic acid ) Patients receive oral bisphosphonate therapy 6 month prior screen ( alendronate ; etidronate ; risedronate ; tiludronate ; ibandronate ) Patients currently receive investigational drug suspect renal toxicity and/or excrete kidney Known clinically significant hypersensitivity zoledronic acid bisphosphonates excipients formulation zoledronic acid ( mannitol , sodium citrate ) Abnormal renal function creatinine clearance Unstable brain metastasis Women childbearing potential use medically recognize form contraception , well woman breastfeed Patients nonmalignant condition would confound evaluation primary endpoint , impair tolerance therapy , prevent compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Bone Metastases</keyword>
	<keyword>Bone Markers</keyword>
	<keyword>NTX</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>Registry</keyword>
	<keyword>Unresectable Stage IV Non Small-cell Lung Cancer ( NSCLC )</keyword>
	<keyword>Unresectable Stage IIIB NSCLC Pleural Effusion</keyword>
</DOC>